Skip to main content
TELA logo

TELA · TELA Bio, Inc.

Track TELA — free
$0.82 -0.04 (-4.64%) At close · Nov 13
Market Cap
$37.06M
Shares
45.19M
Volume · Nov 13 129.18K Avg daily vol (3M) 224.59K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.82 Open$0.82 Day$0.76–0.84 52W close$0.56–1.41 Avg vol 30d148K Short int580K · 1.3% of shares · 5.1d Short vol68% Last earningsNov 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Mar 23, 2027 Est · unconfirmed · in 18 wks

Latest documents

2026
Nov 10
Earnings call
Ovatex aided severe pancreatitis recovery within one to two weeks

TELA described clinician testimony that Ovatex helped a severe pancreatitis patient decompress within one to two weeks, enabled complete abdominal wall closure, and was followed by no recurrent hernia.

3 source passages
# Earnings Call Transcript - TELA Q3 FY2026 So we decided we would use something that's not plastic, that's natural material. We decided to use Ovatex, and after applying that, within one to two weeks, he decompressed. His abdominal wall was pliable enough at that point in time that we could close it completely and then we reinforced it with another piece of matrix on top of that. And even as of today, there's no evidence of any recurrent hernia. Open the document at this passage
Nov 10
Registration statement S-3
Plans $150,000,000 shelf securities offering

TELA Bio, Inc. plans to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants, units and subscription rights. The replacement shelf also covers $90,942,963.70 of unsold securities previously registered before the November 20, 2026 expiration.

Read from the first part of this long document
3 source passages
From time to time, we may offer and sell up to $150,000,000 in the aggregate of any combination of the securities identified above from time to time in one or more offerings. we are registering on this registration statement an aggregate of $90,942,963.70 of unsold securities, or the Unsold Securities, previously registered under the Expiring Registration Statement to be offered, issued and sold by the Company. This registration statement on Form S-3 is being filed TELA Bio, Inc. or the Company, pursuant to Rule 415(a)(6) under the Securities Act of 1933, as amended, or the Securities Act, to replace the Company’s registration statement on Form S-3 (File No. 333-275511), filed with the Securities and Exchange Commission, or SEC, on November 13, 2023, or the Expiring Registration Statement, which is due to expire on November 20, 2026. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 8%; net loss rises 8%

TELA Bio's quarterly revenue fell 8% to $19.0 million and net loss rose 8% to $9.3 million. It implemented cost actions targeting approximately $17.0 million in annual operating-expense reductions through a targeted headcount reduction of approximately 20%.

Revenue $18.96M ▼ 8.4% Net loss $9.3M Diluted EPS -$0.16
Read from the MD&A section
3 source passages
Revenue decreased by $1.7 million, or 8%, to $19.0 million for the three months ended September 30, 2026, from $20.7 million for the three months ended September 30, 2025. Our net loss increased by $0.7 million, or 8%, from $8.6 million for the three months ended September 30, 2025 to $9.3 million for the three months ended September 30, 2026. We announced in August 2026 that we implemented an initiative to strengthen our cost structure and have taken actions to reduce our annual operating expenses by approximately $17.0 million across the organization driven by a targeted headcount reduction of approximately 20% and the streamlining of external resources, while preserving our ability to invest in our core growth priorities and product innovation. Open the document at this passage
Nov 10
Current report 8-K
Revenue falls 8%; cost cuts extend runway into 2028

TELA Bio reported third-quarter 2026 revenue of $19.0 million, down 8% from the prior-year period, while a $17.0 million cost-reduction initiative extends cash runway into 2028. Adjusted EBITDA loss improved 39% to $3.4 million, and cash totaled $22.7 million.

Financial results
5 source passages
TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2026. Revenue was $19.0 million in the third quarter of 2026, a decrease of 8% compared to $20.7 million in the third quarter of 2025. Announced and implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend cash runway into 2028; Adjusted EBITDA loss was $3.4 million in the third quarter of 2026 compared to $5.7 million in the third quarter of 2025, an improvement of 39%. Cash and cash equivalents on September 30, 2026 were $22.7 million. Open the document at this passage
Oct 8
Current report 8-K
Shareholder vote results

On October 8, 2026, TELA Bio, Inc. stockholders approved an amendment authorizing a reverse stock split. The company said it does not intend to effect the split after regaining Nasdaq compliance on October 5, 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$78.18M
Trailing 12 months
Net income (TTM)
−$41.88M
Trailing 12 months
Revenue growth YoY
-8.4%
Year over year
Operating margin
-43.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-92.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$33.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.0%
Year over year · more shares
Price change (1Y)
-26.1%
Trailing year
Short interest
1.3%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 10, 2026
Q3 FY26

TL;DR. International and US hernia revenue growth, lower operating and adjusted EBITDA losses, cost reductions, Nasdaq compliance, 510(k) clearance, favorable clinical results, and market-share gains were positive developments. Revenue and gross margin declined year over year, GAAP net loss widened, interest expense increased, and the company ended the quarter with $22.7 million of cash, current debt of 56,299 (in thousands), and a stockholders' deficit of 24,576 (in thousands).

Bullish
Bearish
  • − Third-quarter revenue decreased 8% year over year, primarily because of lower OviTex PRS volumes.
  • − Gross margin declined to 64.9% from 67.5%, primarily because of a higher excess-and-obsolete-inventory charge.
  • − GAAP net loss widened to $9.3 million from $8.6 million.
  • − Interest expense increased year over year from 1,201 to 2,099 (in thousands).

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −3%
below
Price vs 50-day avg −21%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 31%
mid-range
Momentum
relative strength
Weak
1-month return −16%
trailing
6-month return +1%
trailing
YTD return −31%
this year
Relative strength 0%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
42 of 45 funds reported for Sep 30 · net +404.8K sh shares · +6 new
Insider flow Accumulating
Net +$167.2K over 90 days · 0% sells
Short interest Falling
1.28% of shares out · ▼ -9.3% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
45 holders — mid 3-yr range
Squeeze score 42
elevated · 0–100
Fundamentals
Excellent
Revenue growth +16%
Y/Y
Gross margin 68%
expanding
EPS growth +38%
Y/Y
Free cash flow $-28.7M
Balance sheet $11.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −53%
past year
ATR 16.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 7
Latest guidance · from the 8-K filed May 12, 2026
Full year 2026 revenue growth · Full year 2026 at least 8%
Previous outlook earlier release · from the 8-K filed Mar 24, 2026

Still-open targets the latest release did not restate under the same label.

Revenue growth · full year 2026 at least 8%
Prior guidance period ended · from the Earnings Call filed May 12, 2026
Revenue · Q2 2026 $20M
Guided vs delivered · last 7 settled
Revenue Q2 2026
guided $20M
$19.29M Miss −3.5%
Revenue first quarter 2026
guided $18.5M
$19.06M Beat +3.0%
Revenue full year 2025
guided $85M – $88M
$80.28M Miss −7.2%
Full year 2024 revenue full year 2024
guided $74.5M – $76.5M
$69.3M Miss −8.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−3% Neutral
Price vs 50-day avg
−21% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
31% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
42 of 45 funds reported for Sep 30 · net +404.8K sh shares · +6 new
Insider flow Accumulating
Net +$167.2K over 90 days · 0% sells
Short interest Falling
1.28% of shares out · ▼ -9.3% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
45 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 31% Range high $1
vs 200-day avg -3% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
OviTex PRS units sold 1,050 the three months ended June 30, 2026 filing —
OviTex units sold 5,776 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TELA
TELA Bio, Inc.
this stock
$37.06M -30.5% +15.8% — 1.3%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
48
% held
57.9%
Reported
42 of 45
Top holder
Essex Woodlands Managemen…
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Falling
Shares short
579.6K
Days to cover
5.1d
Change
-59.4K sh
View
Short Volume
Short vol %
68%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
2.4K
Value
$2.8K
As of
Oct 6, 2026
View
Off-Exchange
Off-exchange %
50.4%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$167.2K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$80.3M
Net income (FY)
$-38.8M
EPS diluted
$-0.83
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 10, 2026
This year
25

TELA Bio reported third-quarter 2026 revenue of $19.0 million, down 8% from the prior-year period, while a $17.0 million cost-reduction initiative extends cash runway into 2028. Adjusted EBITDA loss improved 39% to $3.4 million, and cash totaled $22.7 million.

View
Proposed Sales
Value
$2.2M
Shares
428.4K
Filed
Jun 28, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
TELA Bio Announces Inducement Gra…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
TELA +0.0% -15.9% +0.8% +1.2% -30.5%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -2.6% -14.7% +0.3% +1.4% -41.1%
Key facts CIK 1561921 CUSIP 872381108 13F (30d) 42 filings 38 filers Visit website Investor relations